Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial

Stroke

Volumn 39, Issue 6, 2008, Pages 1827-1833

  Shinohara, Yukito ^a   Nishimaru, Katsuya ^b   Sawada, Tohru ^c   Terashi, Akiro ^d   Handa, Shunnosuke ^e   Hirai, Shunsaku ^f   Hayashi, Kunihiko ^f   Tohgi, Hideo ^g   Fukuuchi, Yasuo ^h   Uchiyama, Shinichiro ⁱ   Yamaguchi, Takenori ^j   Kobayashi, Shotai ^k   Kondo, Kazuoki ^l   Otomo, Eiichi ^m   Gotoh, Fumio ⁿ  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c Aino Hospital   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e TOKAI UNIVERSITY TOKYO HOSPITAL   (Japan)

^f GUNMA UNIVERSITY   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

^h ASHIKAGA RED CROSS HOSPITAL   (Japan)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^j NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^k SHIMANE UNIVERSITY HOSPITAL   (Japan)

^l MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^m Yokufukai Geriatric Hospital   (Japan)

ⁿ KEIO UNIVERSITY   (Japan)

more..

Author keywords

Antiplatelet agents; Cerebrovascular diseases stroke; Clinical studies; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PLACEBO; SARPOGRELATE; SEROTONIN RECEPTOR; SEROTONIN ANTAGONIST; SUCCINIC ACID DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEADACHE; HUMAN; HYPERTENSION; JAPAN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; RHINOPHARYNGITIS; SECONDARY PREVENTION; STOMACH ULCER; SUBCUTANEOUS HEMORRHAGE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; INCIDENCE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ASPIRIN; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECEPTORS, SEROTONIN; RECURRENCE; SEROTONIN ANTAGONISTS; SUCCINATES; TREATMENT OUTCOME;

EID: 46249118961     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.107.505131     Document Type: Article

References (27)

1. World Health Organization. The World Health Report 2002-Reducing Risks, Promoting Healthy Life. Available at: http://www.who.int/entity/ whr/2002;170-232. Accessed on March 22, 2008.
2. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myo-cardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
5. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
6. CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE): CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
7. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367: 1665-1673.
8. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
9. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;80: 1930-1935.
10. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593.
11. Furukawa K, Tanabe T, Hoshino S, Mishima Y, Shionoya S, Yoshizaki S, Katsumura T, Nakashima M. Therapeutic effects of sarpogrelate hydrochloride (MCI-9042) on chronic arterial occlusive disease: a double-blind comparison with ticlopidine hydrochloride. Jpn J Clin Pharmacol Ther. 1991;7:1747-1770 (in Japanese).
12. 2C receptor subtypes by molecular modeling. Life Sci. 2003;73: 193-207.
13. Hara H, Osakabe M, Kitajima A, Tamao Y, Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost. 1991;65:415-420.
14. Nishihira K, Yamashita A, Tanaka N, Kawamoto R, Imamura T, Yamamoto R, Eto T, Asada Y. Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery. J Thromb Haemost. 2006;4:247-255.
15. Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost. 1991;66:484-488.
16. 2A antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study. Cere-brovasc Dis. 2007;24:264-270.
17. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003;34:2349-2354.
18. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, Fukuyama T, Doi Y, Mochizuki S, Izumi T, Takekoshi N, Yoshida K, Hiramori K, Origasa H, Uchiyama S, Matsumoto M, Yamaguchi T, Hori M; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37:447- 451.
19. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke. 1990;21: 637-676.
20. Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T, Yamaguchi T, Nishimaru K, Ohhashi Y. Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000;9:147-157.
21. Shinohara Y. Regional differences in incidence and management of stroke: is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis. 2006;21(suppl 1):17-24.
22. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments, part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455-463.
23. Hung HMJ, Wang S-J. Tsong Y, J Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med. 2003;22:213-225.
24. Hata J, Tanizaki Y, Kiyohara Y, Kato I, Kubo M, Tanaka K, Okubo K, Nakamura H, Oishi Y, Ibayashi S, Iida M. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psychiatry. 2005;76:368-372.
25. Hara K, Hirowatari Y, Yoshika M, Komiyama Y, Tsuka Y, Takahashi H. The ratio of plasma to whole-blood serotonin may be a novel marker of atherosclerotic cardiovascular disease. J Lab Clin Med. 2004;144:31-37.
26. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation. 1999;100: 483-489.
27. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.